**8. Conclusion**

HF is still a significant factor in life expectancy, especially among diabetic patients. HF can be viewed as both a cause and a complication of DM at the same time. Evidence strongly suggest that there is negative predictive effect of DM in the course of HF. Therapy for this category of patients should be characterized by a holistic approach, including a thorough glycemic control, as well as an effective blockade of neurohumoral changes. New pharmacological options, such as SGLT2 inhibitors, are allowing for better control of this life-threatening T2D condition. Biomarkers like NTproBNP can help identify HF early and predict prognosis and therapeutic efficacy of HF or/and diabetes treatment. As a result, NT-proBNP testing should be used early in the monitoring of subjects with diabetes with a high CV risk.
